2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaCharacterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.Peer-Reviewed Original ResearchPhase 3 randomized clinical trialPhase 3 RCTsPrimary endpointClinical trialsEligible publicationsProlific authorsSystemic anticancer therapySuccess rateMann-Whitney U testStandard of carePositive publication biasTrial sample sizePositive resultsYear of publicationPublication biasTherapeutic advancesPrimary outcomeAuthorship patternAnticancer therapyExperimental armAuthor's outputMann-WhitneyU testInterquartile rangeAuthor informationEvaluation of the study of control arms in randomized clinical trials of cancer.
Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.Peer-Reviewed Original ResearchRandomized clinical trialsSystemic anti-cancer therapyCancer randomized clinical trialsControl armSuccess rateClinical trials of cancerFisher's exact testAnti-cancer therapyTrial success ratesStudy publication yearExact testPatient convenienceRegimensClinical trialsHighest success rateExperimental armCancer typesCancerContext of treatmentPublication yearTrialsDoseNon-cancerEfficacyDyads
2023
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original ResearchSethi TK, Kothari S , Mulvey E, Foss F, Leonard J, Greer J. Non-Hodgkin Lymphoma in Adults
Means, Robert T.(2023). Wintrobe's Clinical Hematology (15th Edition). Lippincott Williams & Wilkins (LWW).ChaptersPrimary Cutaneous Lymphomas
Perez & Brady's Principles and Practice of Radiation Oncology (8th edition). In Press.Chapters
2022
A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.Peer-Reviewed Original ResearchHuman herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administrationSafety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complicationsFoss F , Sethi T , Girardi M, Wilson, L. Cutaneous Lymphomas
DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology( 2022,12th edition). Lippincott Williams & Wilkins (LWW).Chapters
2021
Chemotherapy Knowledge Base Management in the Era of Precision Oncology.
Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/cci.20.00076.Peer-Reviewed Original ResearchA Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus
Dittus C, Grover N, Sethi T, Cohen J, Voloschin A, Rabadey J, Tan X, Beaven A, Park S. A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. Blood 2021, 138: 1457. DOI: 10.1182/blood-2021-145133.Peer-Reviewed Original ResearchPrimary CNS lymphomaWhole-brain radiation therapyHD-MTXNon-Hodgkin lymphomaReal-world survivalPCNSL groupMedian PFSAntiretroviral therapyWorse OSPerformance statusEntire cohortAstra ZenecaDiffuse large B-cell lymphoma histologyExact testPrimary central nervous system lymphomaAutologous stem cell transplantExtranodal non-Hodgkin lymphomaCentral nervous system lymphomaLactose dehydrogenaseSignificant differencesCentral nervous system tumorsSeattle GeneticsAdvisory CommitteeDeep structure involvementHD-MTX treatmentNo Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis
Allen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.Peer-Reviewed Original ResearchMF/SSWhite blood cell countB patientsNB patientsMedian survivalSézary syndromeInferior survivalSystemic therapyMycosis fungoidesBlack patientsInsurance statusSeattle GeneticsExact testMultivariate Cox proportional hazards modelT-cell receptor clonalityHigh rateCox proportional hazards modelAdvisory CommitteeHigher nodal stageLarge registry studyHigh-risk featuresMulticenter retrospective analysisNumber of comorbiditiesYear of diagnosisKaplan-Meier curvesImpact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
Hill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.Peer-Reviewed Original ResearchCAR T-cell therapyDiffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyLarge B-cell lymphomaT-cell therapyCAR-T therapyB-cell lymphomaInferior PFSR diseaseBristol-Meyers SquibbCurrent equity holderADC therapeuticsCell therapySpeakers bureauBristol-Myers SquibbKite PharmaDLBCL patientsTreatment outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyCD19 chimeric antigen receptor (CAR) T-cell therapyIntroduction Diffuse large B-cell lymphomaPre-treatment tumor biopsiesRelapsed/refractory (R/R) diseaseCAR T-cell infusionAdvisory CommitteeEPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas
Sethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas. Blood 2021, 138: 4547. DOI: 10.1182/blood-2021-151238.Peer-Reviewed Original ResearchAggressive T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAngioimmunoblastic T-cell lymphomaAdult T-cell leukemia/lymphomaProgression-free survivalOverall response rateNon-Hodgkin lymphomaResponse rateR settingOverall survivalCR rateAdverse effectsPanniculitis-like T-cell lymphomaGrade 3 adverse effectsGrade 4 adverse effectsMedian progression-free survivalAllogeneic stem cell transplantPeripheral T-cell lymphomaT-cell leukemia/lymphomaYale-New Haven HospitalFirst lineEfficacy of etoposidePrimary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites
Desai M, Sethi T, Yenamandra A, Morgan D, Thompson M, Reddy N, Kovach A. Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal Of Hematopathology 2021, 14: 269-275. DOI: 10.1007/s12308-021-00473-5.Peer-Reviewed Original ResearchLarge B-cell lymphomaB-cell lymphomaHigh-grade B-cell lymphomaCell lymphomaSinonasal tractDLBCL-NOSAnatomic sitesAnatomic locationExtranodal NK/T-cell lymphomaNK/T-cell lymphomaGerminal center B-cell phenotypeMaxillary sinus tumorsT-cell lymphomaB-cell phenotypeClassification of lymphomasNon-GCB tumorsStage IIEFemale patientsSinus tumorLymphoma characteristicsSitu hybridization studiesWHO criteriaNasopharyngeal diseaseWHO classificationVariable presentationHow we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2020
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMode of deliveryCancer vaccinesImmune checkpoint blockade agentsCheckpoint blockade agentsDifferent cancer vaccinesNeoantigen-based vaccinesRecent preclinical advancesCancer vaccine trialsCancer vaccine fieldLittle clinical activityPromising preclinical resultsMultiple cancer typesCheckpoint blockadeImmunotherapeutic trialsPreclinical advancesTherapeutic vaccinesVaccine trialsClinical activityPreclinical resultsClinical strategiesTherapeutic outcomesVaccine fieldClinical effortsVaccineCancer typesTrends in FDA cancer registration trial design over time, 1969-2020.
Warner J, Sethi T, Rivera D, Venepalli N, Osterman T, Khaki A, Rubinstein S. Trends in FDA cancer registration trial design over time, 1969-2020. Journal Of Clinical Oncology 2020, 38: 2060-2060. DOI: 10.1200/jco.2020.38.15_suppl.2060.Peer-Reviewed Original ResearchTrial designFDA approvalImmunotherapy trialsRegistration trialsCommon trial designOverall survival endpointOncology drug approvalsClass switchFDA package insertsCancer drug indicationsStudy drugCytotoxic therapyControl armTherapeutic approachesPackage insertsRCTsRCT designIndication approvalsOncology drugsLog-linear regressionSurvival endpointsTherapyTrialsDrug approvalNew drugs